In this issue:
Bortezomib consolidation after autologous SCT in MM
Genetic prognostic factors in relapsed MM
Age and organ damage correlate with poor survival in MM
Lenalidomide maintenance in elderly newly diagnosed MM
Treatment recommendations for MM-related bone disease
Auto/RIC-allo vs. autologous SCT in MM
Cereblon and response in MM treated with lenalidomide + dexamethasone
Lenalidomide + dexamethasone for high-risk smouldering MM
Lenalidomide as salvage for relapsed MM after allogeneic SCT
Please login below to download this issue (PDF)